# A Phase I Clinical Study of GLR2037 in Patients With Advanced Prostate Cancer

> **NCT07468396** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Gan & Lee Pharmaceuticals.** · enrollment: 65 (estimated)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** GLR2037

## Key facts

- **NCT ID:** NCT07468396
- **Lead sponsor:** Gan & Lee Pharmaceuticals.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04-30
- **Primary completion:** 2031-10-30
- **Final completion:** 2033-04-30
- **Target enrollment:** 65 (ESTIMATED)
- **Last updated:** 2026-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07468396

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07468396, "A Phase I Clinical Study of GLR2037 in Patients With Advanced Prostate Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07468396. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*